A Phase 1 Open-label 4-Part Study to Evaluate the Effect of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122 in Healthy Adult Subjects

Trial Profile

A Phase 1 Open-label 4-Part Study to Evaluate the Effect of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122 in Healthy Adult Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Avadomide (Primary) ; Fluvoxamine; Itraconazole; Rifampicin
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top